Angle Health Raises $600M to Grow Employer Health Benefits Platform
The $600 million round, led by Vitruvian Partners, signals strong investor confidence in technology for employer-sponsored health benefits.
Angle Health, a company offering a health benefits platform for employers, has raised $600 million in a funding round led by private equity firm Vitruvian Partners. The round also drew participation from Town Hall Ventures, Blumberg Capital, Portage Ventures, PruVen Capital and Y Combinator. The company said the capital will be used to grow its employer health benefits platform, though it did not disclose specific expansion plans.
The size of the raise reflects growing investor interest in technology that simplifies how employers purchase and manage health coverage. Angle Health operates in a competitive segment of the healthcare market, where startups and incumbents alike are vying for employer customers. The involvement of a wide range of investors, from healthcare-focused funds to Y Combinator, suggests confidence in the company's approach.
With this round, Angle Health adds to a series of large raises in the employer benefits space, a sector that continues to attract significant venture capital. The company has not yet detailed how the new funding will be allocated across product development, sales, or geographic expansion.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.